239 related articles for article (PubMed ID: 31691490)
81. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
82. MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Wang X; Wang YZ; Ma KW; Chen X; Li W
Oncol Res Treat; 2014; 37(4):176-80. PubMed ID: 24732641
[TBL] [Abstract][Full Text] [Related]
83. Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
Abdel-Rahman O
Clin Respir J; 2018 Oct; 12(10):2519-2524. PubMed ID: 30073795
[TBL] [Abstract][Full Text] [Related]
84. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
Belani CP; Dahlberg SE; Rudin CM; Fleisher M; Chen HX; Takebe N; Velasco MR; Tester WJ; Sturtz K; Hann CL; Shanks JC; Monga M; Ramalingam SS; Schiller JH
Cancer; 2016 Aug; 122(15):2371-8. PubMed ID: 27163943
[TBL] [Abstract][Full Text] [Related]
85. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
Kawabata S; Connis N; Gills JJ; Hann CL; Dennis PA
Anticancer Res; 2021 Jan; 41(1):91-99. PubMed ID: 33419802
[TBL] [Abstract][Full Text] [Related]
86. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
87. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
88. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
89. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
90. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
91. Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer.
Zhou R; Zhou X; Yin Z; Guo J; Hu T; Jiang S; Liu L; Dong X; Zhang S; Wu G
Oncotarget; 2015 Dec; 6(42):44609-22. PubMed ID: 26587830
[TBL] [Abstract][Full Text] [Related]
92. miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells.
Zhao H; Zhu L; Jin Y; Ji H; Yan X; Zhu X
Acta Biochim Biophys Sin (Shanghai); 2012 Feb; 44(2):177-82. PubMed ID: 22172490
[TBL] [Abstract][Full Text] [Related]
93. Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.
Wang Y; Han X; Wang X; Sheng W; Chen Z; Shu W; Han J; Zhao S; Dai Y; Wang K; Shi W; Yang Z
Jpn J Clin Oncol; 2019 Dec; 49(12):1143-1150. PubMed ID: 31612912
[TBL] [Abstract][Full Text] [Related]
94. Distinct microRNA Signature and Suppression of ZFP36L1 Define ASCL1-Positive Lung Adenocarcinoma.
Enokido T; Horie M; Yoshino S; Suzuki HI; Matsuki R; Brunnström H; Micke P; Nagase T; Saito A; Miyashita N
Mol Cancer Res; 2024 Jan; 22(1):29-40. PubMed ID: 37801008
[TBL] [Abstract][Full Text] [Related]
95. Hypermethylation of adjacent CpG sites is negatively correlated with the expression of lineage oncogene ASCL1 in pulmonary neuroendocrine tumors.
Truong N; Chun SM; Kim TI; Suh YA; Jang SJ
Tumour Biol; 2017 Jun; 39(6):1010428317706225. PubMed ID: 28621224
[TBL] [Abstract][Full Text] [Related]
96. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
[TBL] [Abstract][Full Text] [Related]
97. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
98. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
99. NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer.
Wang LL; Wan XY; Wang TL; Liu CQ; Zheng FM
Med Oncol; 2022 Oct; 39(12):254. PubMed ID: 36224405
[TBL] [Abstract][Full Text] [Related]
100. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
